Roles of Clinical Laboratory Detection in Diagnosis and Treatment of Thyroid Nodule_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 郭林 , 王敏 , 盧仁泉

復旦大學附屬腫瘤醫院檢驗科（上海 200032）;

Corresponding?author：

郭林, Email: guolin500@hotmail.Com

Keywords：

甲狀腺結節; 實驗室檢查; 分子診斷

DOI：

10.7507/1007-9424.20140255

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 郭林, 王敏, 盧仁泉. Roles of Clinical Laboratory Detection in Diagnosis and Treatment of Thyroid Nodule. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(9): 1056-1060. doi: 10.7507/1007-9424.20140255 Copy

1.	American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
2.	中華醫學會內分泌學分會, 中華醫學會外科學分會內分泌學組, 中國抗癌協會頭頸腫瘤專業委員會, 等. 甲狀腺結節和分化型甲狀腺癌診治指南[J]. 中華內分泌代謝雜志, 2012, 28(10):779-797.
3.	上海市疾病預防控制中心. 2009年上海市市區惡性腫瘤發病率[J]. 腫瘤, 2012, 32(10):854.
4.	Frates MC, Benson CB, Doubilet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography[J]. J Clin Endocrinol Metab, 2006, 91(9):3411-3417.
5.	嵇慶海, 王玉龍, 郭智. 甲狀腺癌診治進展[J]. 腫瘤研究與臨床, 2006, 18(3):214-216.
6.	Hamburger JI, Kaplan MM. Diagnosis of thyroid dysfunction in ambulatory patients:primacy of the supersensitive thyroidstimulating hormone assay[J]. Compr Ther, 1990, 16(7):3-7.
7.	Boelaert K, Horacek J, Holder RL, et al. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration[J]. J Clin Endocrinol Metab, 2006, 91(11):4295-4301.
8.	Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage[J]. J Clin Endocrinol Metab, 2008, 93(3):809-814.
9.	史良鳳, 關海霞, 李玉姝, 等. 術前血清促甲狀腺素水平與甲狀腺結節良惡性關系的研究[J]. 中華內分泌代謝雜志, 2010, 26(3):213-214.
10.	NCCN. NCCN clinical practice guidelines in oncology (thyroid carcinoma). Version 1.2013[S]. NCCN, 2013:1-56.
11.	莊大勇. Tg與分化型甲狀腺癌的研究進展[J]. 放射免疫學雜志, 2012, 25(5):532-535.
12.	Baker LJ, Gill AJ, Chan C, et al. Parasitic thyroid nodules:cancer or not?[J]. Endocrinol Diabetes Metab Case Rep, 2014, 2014:140027.
13.	高明. 甲狀腺癌的診療進展及策略[J]. 中華耳鼻咽喉頭頸外科雜志, 2010, 45(11):887-890.
14.	Camargo RY, Tomimori EK. Usefulness of ultrasound in the diagnosis and management of well-differentiated thyroid carcinoma[J]. Arq Bras Endocrinol Metabol, 2007, 51(5):783-792.
15.	Alzahrani AS, Mohamed G, Al Shammary A, et al. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer[J]. J Endocrinol Invest, 2005, 28(6):540-546.
16.	趙勇, 陳波, 黃迅, 等. 促甲狀腺素及甲狀腺自身抗體水平與甲狀腺結節良惡性的關系[J]. 中國現代醫學雜志, 2012, 22(8):41-44.
17.	楊士軍, 譚維琴, 劉滿慶. TGA、TPOAb、TRAb測定對甲狀腺疾病的診斷價值[J]. 放射免疫學雜志, 2008, 21(4):321-322.
18.	Spencer CA. Clinical review:clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC)[J]. J Clin Endocrinol Metab, 2011, 96(12):3615-3627.
19.	Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway[J]. J Am Coll Surg, 2007, 204(5):764-775.
20.	Santarpia L, Gagel RF, Sherman SI, et al. Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer[J]. Head Neck, 2009, 31(3):419-423.
21.	薛聲能, 雷娟, 李娜, 等. 降鈣素和癌胚抗原聯合檢測在甲狀腺髓樣癌診治中的意義[J]. 中國衛生檢驗雜志, 2012, 22(7):1620-1621, 1624.
22.	Roy M, Chen H, Sippel RS. Current understanding and management of medullary thyroid cancer[J]. Oncologist, 2013,18(10):1093-1100.
23.	Barbet J, Campion L, Kraeber-Bodéré F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doublingtimes in patients with medullary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2005, 90(11):6077-6084.
24.	Caria P, Dettori T, Frau DV, et al. Assessing RET/PTC in thyroid nodule fine-needle aspirates:the FISH point of view[J]. Endocr Relat Cancer, 2013, 20(4):527-536.
25.	尹香利. BRAF基因與甲狀腺癌臨床及其預后關系的分子生物學研究[D]. 石河子:石河子大學, 2006.
26.	Kim MI, Alexander EK. Diagnostic use of molecular markers in the evaluation of thyroid nodules[J]. Endocr Pract, 2012, 18(5):796-802.
27.	Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement[J]. Cell, 1985, 42(2):581-588.
28.	Zou M, Baitei EY, Alzahrani AS, et al. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma[J]. Thyroid, 2014,[Epub ahead of print].
29.	左慶瑤, 高燕明, 劉寶岳, 等. 乳頭狀甲狀腺癌BRAFV600E突變的表達及意義[J]. 中華內科雜志, 2009, 48(5):412-413.
30.	Jang EK, Song DE, Sim SY, et al. NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma[J]. Thyroid, 2014,[Epub ahead of print].
31.	Xing M. BRAF V600E mutation and papillary thyroid cancer[J]. JAMA, 2013, 310(5):535.
32.	Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma[corrected] [J]. Science, 2000, 289(5483):1357-1360.
33.	Asaad NY, Abd El-Wahed MM, Mohammed AG. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid carcinoma:diagnostic and prognostic role[J]. J Egypt Natl Canc Inst, 2006, 18(1):8-16.
34.	Teng L, Specht MC, Barden CB, et al. Antisense hTERT inhibits thyroid cancer cell growth[J]. J Clin Endocrinol Metab, 2003, 88(3):1362-1366.
35.	Sugishita Y, Kammori M, Yamada O, et al. Biological differential diagnosis of follicular thyroid tumor and Hürthle cell tumor on the basis of telomere length and hTERT expression[J]. Ann Surg Oncol,2014,21(7):2318-2325.

1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
2. 中華醫學會內分泌學分會, 中華醫學會外科學分會內分泌學組, 中國抗癌協會頭頸腫瘤專業委員會, 等. 甲狀腺結節和分化型甲狀腺癌診治指南[J]. 中華內分泌代謝雜志, 2012, 28(10):779-797.
3. 上海市疾病預防控制中心. 2009年上海市市區惡性腫瘤發病率[J]. 腫瘤, 2012, 32(10):854.
4. Frates MC, Benson CB, Doubilet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography[J]. J Clin Endocrinol Metab, 2006, 91(9):3411-3417.
5. 嵇慶海, 王玉龍, 郭智. 甲狀腺癌診治進展[J]. 腫瘤研究與臨床, 2006, 18(3):214-216.
6. Hamburger JI, Kaplan MM. Diagnosis of thyroid dysfunction in ambulatory patients:primacy of the supersensitive thyroidstimulating hormone assay[J]. Compr Ther, 1990, 16(7):3-7.
7. Boelaert K, Horacek J, Holder RL, et al. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration[J]. J Clin Endocrinol Metab, 2006, 91(11):4295-4301.
8. Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage[J]. J Clin Endocrinol Metab, 2008, 93(3):809-814.
9. 史良鳳, 關海霞, 李玉姝, 等. 術前血清促甲狀腺素水平與甲狀腺結節良惡性關系的研究[J]. 中華內分泌代謝雜志, 2010, 26(3):213-214.
10. NCCN. NCCN clinical practice guidelines in oncology (thyroid carcinoma). Version 1.2013[S]. NCCN, 2013:1-56.
11. 莊大勇. Tg與分化型甲狀腺癌的研究進展[J]. 放射免疫學雜志, 2012, 25(5):532-535.
12. Baker LJ, Gill AJ, Chan C, et al. Parasitic thyroid nodules:cancer or not?[J]. Endocrinol Diabetes Metab Case Rep, 2014, 2014:140027.
13. 高明. 甲狀腺癌的診療進展及策略[J]. 中華耳鼻咽喉頭頸外科雜志, 2010, 45(11):887-890.
14. Camargo RY, Tomimori EK. Usefulness of ultrasound in the diagnosis and management of well-differentiated thyroid carcinoma[J]. Arq Bras Endocrinol Metabol, 2007, 51(5):783-792.
15. Alzahrani AS, Mohamed G, Al Shammary A, et al. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer[J]. J Endocrinol Invest, 2005, 28(6):540-546.
16. 趙勇, 陳波, 黃迅, 等. 促甲狀腺素及甲狀腺自身抗體水平與甲狀腺結節良惡性的關系[J]. 中國現代醫學雜志, 2012, 22(8):41-44.
17. 楊士軍, 譚維琴, 劉滿慶. TGA、TPOAb、TRAb測定對甲狀腺疾病的診斷價值[J]. 放射免疫學雜志, 2008, 21(4):321-322.
18. Spencer CA. Clinical review:clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC)[J]. J Clin Endocrinol Metab, 2011, 96(12):3615-3627.
19. Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway[J]. J Am Coll Surg, 2007, 204(5):764-775.
20. Santarpia L, Gagel RF, Sherman SI, et al. Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer[J]. Head Neck, 2009, 31(3):419-423.
21. 薛聲能, 雷娟, 李娜, 等. 降鈣素和癌胚抗原聯合檢測在甲狀腺髓樣癌診治中的意義[J]. 中國衛生檢驗雜志, 2012, 22(7):1620-1621, 1624.
22. Roy M, Chen H, Sippel RS. Current understanding and management of medullary thyroid cancer[J]. Oncologist, 2013,18(10):1093-1100.
23. Barbet J, Campion L, Kraeber-Bodéré F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doublingtimes in patients with medullary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2005, 90(11):6077-6084.
24. Caria P, Dettori T, Frau DV, et al. Assessing RET/PTC in thyroid nodule fine-needle aspirates:the FISH point of view[J]. Endocr Relat Cancer, 2013, 20(4):527-536.
25. 尹香利. BRAF基因與甲狀腺癌臨床及其預后關系的分子生物學研究[D]. 石河子:石河子大學, 2006.
26. Kim MI, Alexander EK. Diagnostic use of molecular markers in the evaluation of thyroid nodules[J]. Endocr Pract, 2012, 18(5):796-802.
27. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement[J]. Cell, 1985, 42(2):581-588.
28. Zou M, Baitei EY, Alzahrani AS, et al. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma[J]. Thyroid, 2014,[Epub ahead of print].
29. 左慶瑤, 高燕明, 劉寶岳, 等. 乳頭狀甲狀腺癌BRAFV600E突變的表達及意義[J]. 中華內科雜志, 2009, 48(5):412-413.
30. Jang EK, Song DE, Sim SY, et al. NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma[J]. Thyroid, 2014,[Epub ahead of print].
31. Xing M. BRAF V600E mutation and papillary thyroid cancer[J]. JAMA, 2013, 310(5):535.
32. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma[corrected] [J]. Science, 2000, 289(5483):1357-1360.
33. Asaad NY, Abd El-Wahed MM, Mohammed AG. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid carcinoma:diagnostic and prognostic role[J]. J Egypt Natl Canc Inst, 2006, 18(1):8-16.
34. Teng L, Specht MC, Barden CB, et al. Antisense hTERT inhibits thyroid cancer cell growth[J]. J Clin Endocrinol Metab, 2003, 88(3):1362-1366.
35. Sugishita Y, Kammori M, Yamada O, et al. Biological differential diagnosis of follicular thyroid tumor and Hürthle cell tumor on the basis of telomere length and hTERT expression[J]. Ann Surg Oncol,2014,21(7):2318-2325.

Previous Article
Diagnosis and Management of Thyroid Nodules in China
Next Article
Significance of Ultrasonographic Diagnosis in Thyroid Nodules

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Roles of Clinical Laboratory Detection in Diagnosis and Treatment of Thyroid Nodule

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content